These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 16293880)

  • 1. Pathogenesis of myelofibrosis with myeloid metaplasia.
    Tefferi A
    J Clin Oncol; 2005 Nov; 23(33):8520-30. PubMed ID: 16293880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
    Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
    Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
    Chagraoui H; Wendling F; Vainchenker W
    Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease.
    Vannucchi AM; Migliaccio AR; Paoletti F; Chagraoui H; Wendling F
    Semin Oncol; 2005 Aug; 32(4):365-72. PubMed ID: 16202682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement.
    Martyré MC; Le Bousse-Kerdilès MC;
    Semin Oncol; 2005 Aug; 32(4):373-9. PubMed ID: 16202683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis.
    Kakumitsu H; Kamezaki K; Shimoda K; Karube K; Haro T; Numata A; Shide K; Matsuda T; Oshima K; Harada M
    Leuk Res; 2005 Jul; 29(7):761-9. PubMed ID: 15927672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.
    Ho CL; Arora B; Hoyer JD; Wellik LE; Mesa RA; Tefferi A
    Eur J Haematol; 2005 Jan; 74(1):35-9. PubMed ID: 15613104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pathogenesis and drug treatment of myelofibrosis.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
    Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
    Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired GATA-1 expression and myelofibrosis in an animal model.
    Vannucchi AM; Bianchi L; Paoletti F; Di Giacomo V; Migliaccio G; Migliaccio AR
    Pathol Biol (Paris); 2004 Jun; 52(5):275-9. PubMed ID: 15217713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia.
    Martyré MC
    Curr Hematol Rep; 2003 May; 2(3):257-63. PubMed ID: 12901348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches in the treatment of myelofibrosis.
    Hennessy BT; Thomas DA; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2005 Jan; 103(1):32-43. PubMed ID: 15565565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
    Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
    Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes.
    Castro-Malaspina H; Moore MA
    Nouv Rev Fr Hematol (1978); 1982; 24(4):221-6. PubMed ID: 6292827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.
    Yoon SY; Li CY; Lloyd RV; Tefferi A
    Int J Hematol; 2000 Oct; 72(3):337-42. PubMed ID: 11185990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.